🔬 Green Elephant Biotech proposes a solution: CellScrew. This innovative platform improves scalability and reduces labor. 👩🔬
🤝 Partnering with Bürkert, they aim to create an automated system, enhancing reliability in producing vital therapies. 🚀
Introduction:
The article discusses the challenges and advancements in culturing adherent cells, which are crucial for biopharmaceutical production, specifically in cell and gene therapies. It highlights a novel platform developed to enhance the scalability and efficiency of adherent cell cultures, addressing current limitations with existing technologies.
- Adherent cells are pivotal in biopharmaceuticals, particularly in the production of viral vectors for cell and gene therapies, accounting for approximately 70% of such applications.
- Current culturing technologies face significant scaling issues, leading to high costs and inefficiencies in the production processes.
- Existing options for scaling include cumbersome 2D systems or complex 3D processes, both of which present various operational challenges.
- Green Elephant Biotech has developed a novel system called CellScrew, which offers a scalable and dynamic cell culture solution that mitigates scaling issues and reduces time-to-market for therapeutics.
- A collaboration with Bürkert Fluid Control Systems aims to transform CellScrew into a fully automated system, integrating advanced monitoring and control capabilities to enhance reliability and reduce manual labor in biopharmaceutical production.
Conclusion:
The advancements in adherent cell culturing technology represent a significant step toward addressing current production bottlenecks in gene and cell therapies. By streamlining processes and enhancing scalability, innovations like CellScrew could improve access to critical therapies and potentially reduce overall costs within the biopharmaceutical industry.
